0      0

eSymposia | Antibodies and Vaccines as Drugs for COVID-19

Cross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody

Jan 13, 2021 9:30am ‐ Jan 13, 2021 9:45am


You must be logged in and own this session in order to post comments.

Leo OzurumbaDwight
1/13/21 11:25 am

Good day sir, Dr Davide Conti. Imoressive study and insight from your research team. I have few questions to help me understand some areas and give few suggestions: **One antibody (named S309) potently neutralized SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein, from a study by your team published in nature : Dora Pinto, Young-Jun Park, ... Davide Corti Nature volume 583, pages290–295(2020. This means that your prototype Monoclonal antibody design with this quality should take care of most of these emerging mutatnts if not all, such as the ones with extreme level of mutations-which we don't know yet if it will defend the body and clear them. We hope for good news from this mAb construct S309 from your team. This makes me understand the concept of cross protection better. 1) What are the qualities of this mAb that confeted cross protective capacity on it ? 2) The cocktail that included S309 did better in protection against Covid-19. This depicted Cryo-EM structures of the SARS-CoV-2 S glycoprotein in complex with the S309 neutralizing mAb Fab fragment. It's commendable approach and some nice work. We hope your team push further for success: from the benchsude to the bedside., translational immunoscience. Warm regards sir. Leo Ozurumba-Dwight. Walden University MN US